IDEAYA Biosciences Doses First Patient in IDE574 Trial
South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...
Precision Oncology
Advertisement
Agilent Wins FDA Approval for PD-L1 22C3 Test
Santa Clara, USA – March 26, 2026 Agilent Technologies announced U.S. FDA approval of its PD-L1 IHC 22C3 pharmDx...
iDEL Therapeutics Raises €9M to Advance Cancer Pipeline
DORTMUND, Germany, March 17, 2026 iDEL Therapeutics announced the successful close of a €9 million seed financing round led...
Tempus Study Shows Genomic Profiling Expands Cancer Care
CHICAGO — March 11, 2026 Tempus AI, Inc., a technology company focused on advancing precision medicine through artificial intelligence...
Allarity Therapeutics Secures $20M to Advance Stenoparib
TARPON SPRINGS, Fla., March 6, 2026 Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the successful closing of...
Advertisements
AI Cancer Analysis Gains CPT Code for Oncology Decisions
MADISON, Wis., March 3, 2026 AI-powered oncology analytics reached a new milestone as AIQ Solutions announced that the American...
Blood Test Tracks Immunotherapy Response in Solid Tumors
FOSTER CITY, Calif., March 3, 2026 Adela, Inc. has announced the publication of new clinical validation data in npj...
FDA Grants Priority Approval to Hernexeos for NSCLC
WASHINGTON, D.C., February 26, 2026 The U.S. Food and Drug Administration (FDA) has granted approval to Hernexeos (zongertinib) for...
Caris Detect Achieves 99% Specificity in MCED
IRVING, Texas, February 26, 2026 Caris Life Sciences® (NASDAQ: CAI) announced an interim readout from its Achieve 1 clinical...
H&N Cancer Market to Reach $2.6B by 2032
PUNE, India, February 26, 2026 The global head and neck cancer therapeutics market is projected to grow from USD...
Advertisement
